All the Active Ingredient Drugs
Parathyroid Hormone Analog. Teriparatide 20 mcg/dose. MULTIDOSE PREFILL. PEN INJECT: 1. 20 μg S.C. dly. Discard pen aft. 28 days.
Tmt. postmenopaus. osteoporos. in pts.
at high risk of fracture. To incr. bone
mass in men with prim. or hypogonad.
Osteoporos. at high risk of fracture.
Tmt. osteoporos. assoc. with sustained system. glucocorticoid ther. in women/ men at incr. risk fracture.
C/I: Hypersens, Preg., lact., Sev.
ren. failure, osteosarc., pediat. pts.,
see lit.
Parathyroid hormone analogue. Teriparatide 250 mcg/ml. PRE-FILL. PEN (sol. for S.C. inj.):1,3. The usual. dose one S.C. inj. dly., in the thigh or lower abdomen. See lit.
Tmt . of postmenopaus. women with osteoporosis at high risk for frac., defined as a history of osteoporotic frac., multiple risk fact. for frac., or pts. who have failed or are intoler. to other available osteoporosis ther. In postmenopaus. women with osteoporosis, Teriparatide increas. BMD reduces the risk of vertebral and nonvertebral frac.
Indicated to incr. bone mass in men with prim. or hypogonadal osteoporosis at high risk for frac., defined as a history of osteoporotic frac., multiple risk fact. for frac., or pts. who have failed or are intoler.to other available osteoporosis ther.
Tmt. of men & women with osteoporosis associat. with sustained system. glucocorticoid ther. (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for frac., defined as a history of osteoporotic frac., multiple risk fact. for frac., or pts. who have failed or are intoler.to other available osteoporosis ther.
C/I: Hypersens.
Preg., lact.
Pts. with Paget’s dis., hypercalcem., metabol. bone dis., bone tumors.
Pts. that had underwent radiation ther. for the bones.
Severe renal impair.
Child. or a young pt. in the grow. stage.
Hyperparathyroidism.
Parathyroid hormone analogue. Teriparatide 20 mcg/dose. cartridge 2.4 ml X 1, starter box (cartridge 2.4 ml X 1 + Pen X 1)
20 mcg S.C. once a day
Tmt. of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intol. to other available osteoporosis ther. In postmenopausal women with osteoporosis this drug reduces the risk of vertebral and nonvertebral fractures . * To incr. bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, or who have failed or are intol. to other available osteoporosis ther. * Tmt. of men and women with osteoporosis associated with sustained systemic glucocorticoid ther. (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intol. to other available osteoporosis ther.
C/I: Hypersens. See lit.
